Abstract:AACR Centennial Conference: Translational Cancer Medicine-- July 20-23, 2008; Monterey, CA B16 This study is designed to identify and verify heat shock protein 90 (HSP90) pharmacodynamic RNA biomarkers and to develop a single multiplex panel to monitor them in a clinical setting. HSP90 is a ubiquitously expressed molecular chaperone which is involved in multiple cellular functions, such as signal transduction and protein folding. Together with other co-chaperones, HSP90 participates in many key processes in oncogenesis including growth factor independence, stabilization of mutant proteins, angiogenesis, and metastasis, by regulating the maturation and stability of its client proteins. Among HSP90 clients are Her2, v-Src, Bcr-Abl, p53 mutant, VEGF, NOS, MMP2, AKT, and steroid receptors. Multiple cancer drugs have targeted HSP90 to inhibit its activity in cancerous cells, including geldanamycin and its derivatives, and ridicicol. In pre-clinical and clinical development, HSP70, CDK4 and other proteins have been used as single biomarkers to monitor drug activity and response. We have developed a multivariate biomarker development system based on our proprietary multiplex PCR technology, which utilizes Beckman Coulter’s GeXP CEQ platform. Utilizing this process we have identified a set of RNA biomarkers whose in vitro expression in a inhibitor sensitive cell line is significantly altered by the HSP90 inhibitors 17-N-Allylamino-17-demethoxygeldanamycin (17-AAG) and Ridicicol. Their expression changes in a dose and time dependent manner and the changes are not compound specific, suggesting that this panel may have broad utility for therapeutics that target the HSP90 pathway. We have produced a single multiplex assay that is capable of monitoring all of these targets in a single reaction. We have now expanded this study to include additional sensitive and insensitive cell lines for verification, as well as carried out IC50 assays to analyze for correlation to our gene expression results. Additionally, we have designed and carried out experiments to determine the correlation between data obtained in vitro and the drug response seen in vivo . We have successfully verified these biomarkers and correlated their activity to responses measured in IC50 assays. We now plan to begin validation of in vivo responses with human clinical samples.

A Screening Method for Potential Anti-pancreatic Cancer Candidate Compounds Based on Hsp90-Cdc37 Interaction Model in vitro

Screening, Optimization, and ADMET Evaluation of HCJ007 for Pancreatic Cancer Treatment Through Active Learning and Dynamics Simulation

High-Throughput Screening Fluorescence Polarization Assay for Tumor-Specific Hsp90

Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs As Competitive Hsp90 Inhibitors Through Shape-Based Similarity Screening.

Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening.

New Approach for Screening Anti-Tumor Compounds

Efficient Screening of Pancreatic Lipase Inhibitors from Rheum Palmatum by Affinity Ultrafiltration-High-performance Liquid Chromatography Combined with High-Resolution Inhibition Profiling

Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (hsp90) and Cell Division Cycle 37 As Orally Active Inhibitors for the Treatment of Colorectal Cancer.

Verification of a Multivariate Pharmacodynamic Biomarker Assay for HSP90 Inhibitors

Design, Synthesis and Bioevaluation of Inhibitors Targeting HSP90-CDC37 Protein-Protein Interaction Based on a Hydrophobic Core.

Anti-tumor metastasis medicament high flux screening model

In silico identification of small molecule modulators for disruption of Hsp90-Cdc37 protein-protein interaction interface for cancer therapeutic application

Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies

Effective Screening Strategy Using Ensembled Pharmacophore Models Combined with Cascade Docking: Application to P53-Mdm2 Interaction Inhibitors

Studies on the pIC<sub>50</sub> of 4,5-Diarylisoxazole as HSP90 Inhibitors

A Novel Method To Assay Molecular Chaperone Activity Of Hsp70: Evaluation Of Drug Resistance In Cancer Treatment

HTRF-based Method for Determination of HSP90-HOP Inhibition Activity and Its Application

Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.

Optimization and Bioevaluation of Cdc37-derived Peptides: an Insight into Hsp90-Cdc37 Protein-Protein Interaction Modulators.

Integrated Phenotypic Screening and Activity-Based Protein Profiling to Reveal Potential Therapy Targets of Pancreatic Cancer.

Rational design of peptide inhibitors targeting HSP90–CDC37 protein–protein interaction